Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging trial of K-832 in active rheumatoid arthritis
2004-000362-12Phase 2Completed
- Sponsor
- Kowa Research Europe
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of K-832 in rheumatoid arthritis (RA) (4 arms), sponsored by Kowa Research Europe. Primary endpoint: ACR20 response at 16 weeks. Started Aug 2004; status: completed.
02
Drugs
K-832
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2004-000362-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000362-12.